MX2023008153A - Metodos y compuestos para tratar la ataxia de friedreich. - Google Patents

Metodos y compuestos para tratar la ataxia de friedreich.

Info

Publication number
MX2023008153A
MX2023008153A MX2023008153A MX2023008153A MX2023008153A MX 2023008153 A MX2023008153 A MX 2023008153A MX 2023008153 A MX2023008153 A MX 2023008153A MX 2023008153 A MX2023008153 A MX 2023008153A MX 2023008153 A MX2023008153 A MX 2023008153A
Authority
MX
Mexico
Prior art keywords
terminus
compounds
methods
binding
ataxia
Prior art date
Application number
MX2023008153A
Other languages
English (en)
Spanish (es)
Inventor
Chengzhi Zhang
Pratik Shah
Aseem Ansari
Abhi Bhat
Sean Jeffries
Original Assignee
Design Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Design Therapeutics Inc filed Critical Design Therapeutics Inc
Publication of MX2023008153A publication Critical patent/MX2023008153A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
MX2023008153A 2021-01-08 2022-01-07 Metodos y compuestos para tratar la ataxia de friedreich. MX2023008153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135427P 2021-01-08 2021-01-08
PCT/US2022/011560 WO2022150555A2 (en) 2021-01-08 2022-01-07 Methods and compounds for treating friedreich's ataxia

Publications (1)

Publication Number Publication Date
MX2023008153A true MX2023008153A (es) 2023-09-21

Family

ID=82358799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008153A MX2023008153A (es) 2021-01-08 2022-01-07 Metodos y compuestos para tratar la ataxia de friedreich.

Country Status (11)

Country Link
US (1) US20240124491A1 (https=)
EP (1) EP4274583A4 (https=)
JP (1) JP2024502469A (https=)
CN (1) CN117241805A (https=)
AR (1) AR124589A1 (https=)
AU (1) AU2022206424A1 (https=)
CA (1) CA3204523A1 (https=)
IL (1) IL304322A (https=)
MX (1) MX2023008153A (https=)
TW (1) TW202241892A (https=)
WO (1) WO2022150555A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための方法及び化合物
JP2025502064A (ja) * 2022-01-06 2025-01-24 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための化合物及び方法
CN119708005A (zh) * 2023-09-27 2025-03-28 北京沐华生物科技有限责任公司 一类brd4蛋白降解剂化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270727A1 (en) * 2005-05-03 2006-11-30 Christian Melander Small molecule therapeutics and uses therefor
RU2720237C2 (ru) * 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
US10517877B2 (en) * 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
PT3442972T (pt) * 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
WO2019204781A1 (en) * 2018-04-20 2019-10-24 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease
EP4234550A3 (en) * 2018-05-22 2023-09-06 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease
US20220047596A1 (en) * 2018-09-12 2022-02-17 Board Of Regents, The University Of Texas System Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
CN121045206A (zh) * 2020-02-03 2025-12-02 设计治疗公司 用于治疗遗传疾病的方法和化合物
WO2022126000A1 (en) * 2020-12-11 2022-06-16 Design Therapeutics, Inc. Methods and compounds for modulating myotonic dystrophy 1
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための方法及び化合物

Also Published As

Publication number Publication date
CA3204523A1 (en) 2022-07-14
IL304322A (en) 2023-09-01
TW202241892A (zh) 2022-11-01
AU2022206424A1 (en) 2023-08-24
AU2022206424A9 (en) 2024-09-19
WO2022150555A3 (en) 2022-12-22
CN117241805A (zh) 2023-12-15
JP2024502469A (ja) 2024-01-19
WO2022150555A2 (en) 2022-07-14
US20240124491A1 (en) 2024-04-18
EP4274583A4 (en) 2025-01-22
EP4274583A2 (en) 2023-11-15
AR124589A1 (es) 2023-04-12

Similar Documents

Publication Publication Date Title
WO2023133284A3 (en) Compounds and methods for treating friedreich's ataxia
MX2023008153A (es) Metodos y compuestos para tratar la ataxia de friedreich.
EP4234553A3 (en) Methods and compounds for the treatment of genetic disease
EA202090034A1 (ru) Способы модификации сплайсинга рнк
UY26815A1 (es) Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
EP4234550A3 (en) Methods and compounds for the treatment of genetic disease
CY1119614T1 (el) ΟΛΙΓΟΜΕΡΕΙΣ ΕΝΩΣΕΙΣ ΓΙΑ ΤΗ ΔΙΑΜΟΡΦΩΣΗ ΤΗΣ ΕΚΦΡΑΣΗΣ HIF-1α
EA201991309A1 (ru) Способы модуляции сплайсинга рнк
CY1105271T1 (el) Δεσμες λειτουργικης πρωτεϊνης
EP2189471A4 (en) FOXM1 PEPTIDE AND MEDICAMENT THEREFOR
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
WO2005040180A3 (en) Antisense modulation of superoxide dismutase 1, soluble (sod-1) expression
ATE421537T1 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
MX2023015520A (es) Conjugados de oligonucleotidos dirigidos al receptor de transferrina.
BRPI0414810A (pt) composições baseadas no vìrus seneca valley e métodos para tratar doença
DE60133817D1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
NO20044628L (no) Immunglobulindomene som inneholder celleoverflategjenkjennende molekyler
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
MX2024012094A (es) Metodos y compuestos para modular la enfermedad de huntington
BR0313455A (pt) modulação "antisense" da expressão de nav1.3
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
WO2007121326A3 (en) Compositions and methods for modulating gene expression
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.